nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2017 | short review

Novel therapeutics in supportive cancer treatment

verfasst von: Dr. Clemens Dormann

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Summary

With constantly improving cancer therapies, patient’s quality of life, the management of potential side effects and treatment-related symptoms have also made considerable progress. Chemotherapy-induced nausea and vomiting (CINV) still constitutes a major problem for many patients. New developments in the field allow a more comfortable administration of guideline-based antiemetic therapy and may further improve the control of nausea. Therapeutic options for the cancer anorexia–cachexia syndrome (CACS), common in advanced cancers, are still limited and hampered by numerous side effects. Among these, targeting the ghrelin-receptor pathway could be a novel approach; however, data are still immature.

Vorheriger Artikel Chemotherapies and future directions in metastatic colorectal cancer

Nächster Artikel Renal insufficiency in patients with multiple myeloma

Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119–v33. https://doi.org/10.1093/annonc/mdw270.CrossRefPubMed

Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–9. https://doi.org/10.1093/annonc/mdu096.CrossRefPubMedPubMedCentral

Rojas C, Slusher BS. Pharmacological mechanism of 5‑HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684:1–7. https://doi.org/10.1016/j.ejphar.2012.01.046.CrossRefPubMed

Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570–7. https://doi.org/10.1093/annonc/mdg417.CrossRefPubMed

Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy randomized, comparative phase III trial. Lancet Oncol. 2009;10:115–24. https://doi.org/10.1016/S1470-2045(08)70313-9.CrossRefPubMed

Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441–9. https://doi.org/10.1093/annonc/mdl137.CrossRefPubMed

Stathis M, Pietra C, Rojas C, et al. Inhibition of substance P‑mediated responses in NG108–15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012;689:25–30. https://doi.org/10.1016/j.ejphar.2012.05.037.CrossRefPubMed

Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–6. https://doi.org/10.1093/annonc/mdu110.CrossRefPubMedPubMedCentral

Aapro M, Rugo H, Rossi G, et al. A randoized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328–33. https://doi.org/10.1093/annonc/mdu101.CrossRefPubMedPubMedCentral

10.

Aapro M, Karthaus M, Schwartzberg L, et al. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer. 2017;25:1127–35. https://doi.org/10.1007/s00520-016-3502-x.CrossRefPubMed

11.

Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16:1079–89. https://doi.org/10.1016/S1470-2045(15)00035-2.CrossRefPubMed

12.

Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015;16:1071–8. https://doi.org/10.1016/S1470-2045(15)00034-0.CrossRefPubMed

13.

Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–42. https://doi.org/10.1056/NEJMoa1515725.CrossRefPubMedPubMedCentral

14.

Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9:188–95. https://doi.org/10.1016/j.suponc.2011.05.002.CrossRefPubMed

15.

Abe M, Hirashima Y, Kasamatsu Y, et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer. 2016;24:675–82. https://doi.org/10.1007/s00520-015-2829-z.CrossRefPubMed

16.

Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10:90–9. https://doi.org/10.1038/nrclinonc.2012.209.CrossRefPubMed

17.

Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980;69:491–7.CrossRefPubMed

18.

Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83:1345–50.PubMed

19.

LeBlanc TW, Nipp RD, Rushing CN, et al. Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J Pain Symptom Manage. 2015;49:680–9. https://doi.org/10.1016/j.jpainsymman.2014.09.008.CrossRefPubMed

20.

Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920–6. https://doi.org/10.1158/1078-0432.CCR-08-2242.CrossRefPubMed

21.

Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004;90:1905–11. https://doi.org/10.1038/sj.bjc.6601781.CrossRefPubMedPubMedCentral

22.

Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48. https://doi.org/10.1016/j.clnu.2016.07.015.CrossRefPubMed

23.

Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–31. https://doi.org/10.1016/S1470-2045(15)00558-6.CrossRefPubMed

24.

Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;28:CD4310. https://doi.org/10.1002/14651858.CD004310.pub3.

25.

Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005;23:8500–11. https://doi.org/10.1200/JCO.2005.01.8010.CrossRefPubMed

26.

Moertel CG, Schutt AJ, Reitemeier RJ, Hanh RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer. 1974;33:1607–9. https://doi.org/10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V.CrossRefPubMed

27.

Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88:625–36. https://doi.org/10.1016/j.critrevonc.2013.07.015.CrossRefPubMed

28.

Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med. 1997;157:1651–6.CrossRefPubMed

29.

Guillory B, Splenser A, Garcia J. The role of ghrelin in anorexia-cachexia syndromes. Vitam Horm. 2013;92:61–106. https://doi.org/10.1016/B978-0-12-410473-0.00003-9.CrossRefPubMed

30.

Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16:108–16. https://doi.org/10.1016/S1470-2045(14)71154-4.CrossRefPubMed

31.

Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017; https://doi.org/10.1093/annonc/mdx192.PubMed

Titel: Novel therapeutics in supportive cancer treatment
verfasst von: Dr. Clemens Dormann
Publikationsdatum: 01.09.2017
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-017-0353-1

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma

Highlights from the 2017 St. Gallen Breast Cancer Consensus

An Austrian view of the 2017 consensus for the treatment of early breast cancer

Chemotherapies and future directions in metastatic colorectal cancer

New diagnostic tools for breast cancer

Prognostic significance of aberrant expression of CD markers in acute lymphoblastic leukemia